Provided by Tiger Trade Technology Pte. Ltd.

Beyondspring Inc

1.49
-0.0302-1.99%
Post-market: 1.490.00000.00%19:38 EDT
Volume:9.89K
Turnover:15.23K
Market Cap:61.27M
PE:-59.85
High:1.66
Open:1.59
Low:1.46
Close:1.52
52wk High:3.44
52wk Low:1.21
Shares:41.12M
Float Shares:30.22M
Volume Ratio:1.38
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0249
EPS(LYR):-0.0249
ROE:-310.48%
ROA:-18.56%
PB:-1.91
PE(LYR):-59.85

Loading ...

Company Profile

Company Name:
Beyondspring Inc
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
44
Office Location:
100 Campus Drive,4th Floor, Suite 410,West Side,Florham Park,New Jersey,United States
Zip Code:
07932
Fax:
- -
Introduction:
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Directors

Name
Position
Lan Huang
Director,Chairman and Chief Executive Officer
Brendan Delaney
Independent Director
Jiangwen Majeti
Independent Director
Matthew Kirkby
Independent Director
Patrick Fabbio
Independent Director
Sihai Xu
Director

Shareholders

Name
Position
Lan Huang
Director,Chairman and Chief Executive Officer
June Lu
Chief Scientific Officer